Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

May 26, 2017May 26, 2017

Resverlogix Welcomes Study Highlighting Apabetalone for CKD-Related Cardiovascular Disease

News

A new article highlights the mechanism of action of apabetalone to treat cardiovascular disease in patients with chronic kidney disease (CKD), reports Canadian pharmaceutical company Resverlogix. Cardiovascular disease is the main cause of ... Read more

May 24, 2017May 24, 2017

Avacopan Named Orphan Drug in Europe for Potential to Treat C3 Glomerulopathy

News

Avacopan (CCX168) has been designated an orphan medicinal product by the European Medicines Agency (EMA) for the treatment of a severe kidney disease called C3 glomerulopathy (C3G). ChemoCentryx said that a multi-center clinical ... Read more

April 25, 2017April 25, 2017

Cricket Health Says its Modality Choice Program Helps CKD Patients Choose Treatment Plan

News

Education, combined with an integrated patient and provider online community, increases the likelihood that people with late-stage chronic kidney disease (CKD) opt for at-home dialysis, pre-emptive transplant or palliative care instead ... Read more

April 21, 2017

Veltassa Normalizes Blood Potassium in Kidney Disease with or Without Food, Trial Shows

News

Veltassa (patiromer) is an effective treatment against hyperkalemia, or excessive levels of potassium in the blood, whether chronic kidney disease (CKD) patients take it with or without food, a clinical trial ... Read more

April 17, 2017April 17, 2017

Connie Rhee Receives ATA Grant to Study Thyroid Dysfunction, Depression in CKD Patients

News

The American Thyroid Association (ATA) has awarded Connie Rhee, MD, a grant to study how thyroid dysfunctions increase the risk of depression and reduced health-related quality of life in patients ... Read more

April 3, 2017April 3, 2017

Cara’s Intravenous Therapy CR845 Reduces Itching in Uremic Pruritus Patients, Trial Finds

News

Cara Therapeutics announced that treatment with its intravenous drug CR845 reduced itching and improved quality of life in patients suffering from uremic pruritus (UP) associated with chronic kidney disease. These results come ... Read more

March 31, 2017

Positive Data Reported from Phase 2 Trials of Roxadustat for Treatment of Anemia in CKD

News

FibroGen, announced the publication of positive results from two Phase 2 clinical trials of roxadustat, its therapy candidate for the treatment of anemia in patients with chronic kidney disease (CKD). The study with ... Read more

March 29, 2017March 29, 2017

Vadadustat Eases Anemia in Chronic Kidney Disease Patients, Trial Shows

News

Akebia Therapeutics‘ vadadustat (AKB-6548) eased chronic kidney disease (CKD) patients’ anemia, a Phase 2a clinical trial showed. It did this by increasing levels of hemoglobin and improving iron mobilization in CKD patients ... Read more

March 22, 2017

FDA Again Declines to Approve ZS-9 for Lowering Potassium in Blood

News

The U.S. Food and Drug Administration (FDA) has once again declined to approve AstraZeneca’s ZS-9 as a treatment for hyperkalemia, or high levels of potassium in the blood — a ... Read more

March 15, 2017

CKD Patients Don’t Benefit from Intensive Blood Pressure Control, Study Says

News

Blood pressure treatment below the standard accepted level does not offer an additional benefit for renal function in patients with chronic kidney disease (CKD) without diabetes, according to researchers. However, ... Read more

March 10, 2017

Parsabiv Approved in Europe for Secondary Hyperparathyroidism in Adults on Hemodialysis

News

The European Commission (EC) has granted marketing authorization for Parsabiv (etelcalcetide), Amgen’s candidate for treating secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) who are undergoing hemodialysis. Parsabiv is a ... Read more

March 1, 2017

CMHP Favors Approval of AstraZeneca’s Lokelma to Treat Hyperkalemia in Europe

News

Europe’s Committee for Medicinal Products for Human Use (CMPH) has recommended approving AstraZeneca’s Lokelma for the treatment of hyperkalemia (high levels of potassium in the blood), a condition common in patients with chronic kidney ... Read more

February 27, 2017February 27, 2017

Resverlogix Plans Phase 2a Kidney Dialysis Trial of Apabetalone in 2017

News

Resverlogix said it will move ahead with its Phase 2a kidney dialysis trial following a Type B meeting with the Cardiovascular and Renal Products Division of the U.S. Food and Drug Administration ... Read more

February 17, 2017

End-Stage Renal Disease Therapeutic Tenapanor Does Well in Phase 3 Clinical Trial

News

Tenapanor, a therapeutic for end-stage renal disease patients who are on dialysis and have too much phosphate in their blood, was well-tolerated and met the goals of a Phase 3 ... Read more

February 10, 2017

FDA Approves Amgen’s Parsabiv for Secondary Hyperparathyroidism in Adults on Dialysis

News

The U.S. Food and Drug Administration (FDA) has approved Amgen’s Parsabiv (etelcalcetide) to treat adult patients with chronic kidney disease (CKD) who are on dialysis and experience secondary hyperparathyroidism (sHPT). “We are ... Read more

February 6, 2017

Skin’s Sodium Content Linked to Heart Problems in Kidney Disease Patients, Study Shows

News

Sodium intake may be linked with the changes that occur in the heart’s left ventricle of patients with chronic kidney disease (CKD). Interventions that reduce sodium intake, such as reducing ... Read more

January 23, 2017January 23, 2017

Espero Donates GoNitro to ISCHEMIA and ISCHEMIA-CKD Clinical Trials

News

Espero Pharmaceuticals will donate its GoNitro (nitroglycerin) sublingual powder to be used in two clinical trials in patients with stable ischemic heart disease, and in a subgroup of patients who also ... Read more

January 16, 2017January 16, 2017

Tricida’s Therapy Candidate Shows Promise in Restoring Acid-base Balance in Kidney Disease Patients

News

Tricida‘s lead investigational drug TRC101 increased serum bicarbonate levels essential to restoring the acid-base balance in patients with chronic kidney disease (CKD) and metabolic acidosis, according to the results of a study. ... Read more

January 13, 2017

2 Clinical Trials Begin to Evaluate Potential Hyperkalemia Treatment

News

Two trials have been initiated to assess Ardelyx‘s RDX227675 as a treatment for patients with hyperkalemia, a serious condition in people with chronic kidney disease (CKD) and heart failure (HF). ... Read more

January 4, 2017

Health-checks Program Increases Kidney-disease Diagnoses in England

News

A national program in England aimed at reducing cardiovascular disease has led to an 80 percent increase in diagnoses of chronic kidney disease (CKD) in its first five years. The NHS Health ... Read more